Guidelines, Standards & Policy Recommendations
1. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione M. International Standards for Tuberculosis Care. Lancet Infect Dis 2006;6:710-25. [Contributor]. [Link]2. Gardam M, Kunimoto D, Long R, Menzies D, Pai M. Canadian Tuberculosis Committee. Interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep. 2007 Nov 1;33(ACS-10):1-18. [Contributor]. [Link]
3. Pai M, Gardam M, Haldane D, Kitai I, Kunimoto D, Long R, Menzies D, Morshed M, Ward H, Wobeser W. Canadian Tuberculosis Committee. Updated Recommendations on Interferon Gamma Release Assays for Latent Tuberculosis Infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2008;34 (ACS-6):1-13. [Lead Author].
4. World Health Organization. Policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. Geneva, WHO, 2008. [Member, Systematic Reviews Panel] [Link] 5. World Health Organization. Treatment of tuberculosis: Guidelines. 4th Edition. Geneva, WHO, 2009. [Member, Technical Guideline Development Group] [Link]
6. World Health Organization. WHO policy on tuberculosis infection control in health-care facilities, congregate settings and households. Geneva, WHO, 2009. [Member, Systematic Reviews Panel] [Link]
7. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care. 2nd Edition. TBCTA, The Hague, 2009. [Member, Steering Committee] [Link]
8. Al Jahdali H, Baharoon S, Abba A, Memish Z, Alrajhi AA, Barrak AA, Haddad Q, Al Hajjaj M, Pai M, Menzies D. Saudi guidelines for testing and treatment of latent tuberculosis infection. Ann Saudi Med 2010;30:38-49. [Link]
9. Kunimoto D, Gardam M, Kitai I, Menzies D, Morshed M, Pai M, Ward H, Webster D, Wobeser W. Canadian Tuberculosis Committee. Recommendations on Interferon Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection - 2010 Update. Can Commun Dis Rep 2010;36 (ACS-5):1-21. [Contributor].
10. World Health Organization. Policy statement: Fluorescent light emitting diode (LED) microscopy for diagnosis of tuberculosis. Geneva, WHO, 2010. [Member, Systematic Reviews Panel] [Link]
11. World Health Organization. Policy statement: Non-commercial culture and drug-susceptibility testing methods for screening of patients at risk of multidrug-resistant tuberculosis. Geneva, WHO, 2010. [Member, Systematic Reviews Panel] [Link]
12. Kakkar F, Allen UD, Ling D, Pai M, Kitai IC; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Position statement: Tuberculosis in Children: New diagnostic blood tests. Paediatr Child Health 2010;15(8):529-33. [Contributor]
13. Tuberculosis Coalition for Technical Assistance (TBCTA). Implementing the WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households. TBCTA, The Hague, 2010. [Contributor]
14. World Health Organization. Policy statement: Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement. Geneva, WHO, 2011. URL: http://www.who.int/tb/dots/laboratory/policy_statements/en/index.html [Member, Systematic Reviews Panel]
15. World Health Organization. Policy statement: The use of tuberculosis interferon‐gamma release assays (IGRAs) in low‐ and middle‐income countries. Geneva, WHO, 2011. URL: http://www.who.int/tb/dots/laboratory/policy_statements/en/index.html [Member, Systematic Reviews Panel]
16. Stop TB Partnership & World Health Organization. An international roadmap for tuberculosis research: towards a world free of tuberculosis. Geneva, WHO, 2011. [Contributor]
